Search: onr:"swepub:oai:DiVA.org:uu-512437" > Pyronaridine :
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 03337naa a2200325 4500 | |
001 | oai:DiVA.org:uu-512437 | |
003 | SwePub | |
008 | 230926s2023 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-5124372 URI |
024 | 7 | a https://doi.org/10.1093/jac/dkad2602 DOI |
040 | a (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a for2 swepub-publicationtype |
100 | 1 | a Chu, Wan-Yuu Netherlands Canc Inst, Dept Pharm & Pharmacol, Amsterdam, Netherlands.4 aut |
245 | 1 0 | a Pyronaridine :b a review of its clinical pharmacology in the treatment of malaria |
264 | c 2023 | |
264 | 1 | b Oxford University Press,c 2023 |
338 | a electronic2 rdacarrier | |
520 | a Pyronaridine-artesunate was recently strongly recommended in the 2022 update of the WHO Guidelines for the Treatment of Malaria, becoming the newest artemisinin-based combination therapy (ACT) for both uncomplicated Plasmodium falciparum and Plasmodium vivax malaria. Pyronaridine-artesunate, available as a tablet and paediatric granule formulations, is being adopted in regions where malaria treatment outcome is challenged by increasing chloroquine resistance. Pyronaridine is an old antimalarial agent that has been used for more than 50 years as a blood schizonticide, which exerts its antimalarial activity by interfering with the synthesis of the haemozoin pigment within the Plasmodium digestive vacuole. Pyronaridine exhibits a high blood-to-plasma distribution ratio due to its tendency to accumulate in blood cells. This feature is believed to play a crucial role in its pharmacokinetic (PK) properties and pharmacological activity. The PK characteristics of pyronaridine include rapid oral absorption, large volumes of distribution and low total body clearance, resulting in a long terminal apparent half-life. Moreover, differences in PK profiles have been observed between healthy volunteers and malaria-infected patients, indicating a potential disease-related impact on PK properties. Despite a long history, there is only limited knowledge of the clinical PK and pharmacodynamics of pyronaridine, particularly in special populations such as children and pregnant women. We here provide a comprehensive overview of the clinical pharmacology of pyronaridine in the treatment of malaria. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Farmakologi och toxikologi0 (SwePub)301022 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Pharmacology and Toxicology0 (SwePub)301022 hsv//eng |
700 | 1 | a Dorlo, Thomas P. C.,c PhD,d 1983-u Uppsala universitet,Institutionen för farmaci,Netherlands Canc Inst, Dept Pharm & Pharmacol, Amsterdam, Netherlands4 aut0 (Swepub:uu)thodo249 |
710 | 2 | a Netherlands Canc Inst, Dept Pharm & Pharmacol, Amsterdam, Netherlands.b Institutionen för farmaci4 org |
773 | 0 | t Journal of Antimicrobial Chemotherapyd : Oxford University Pressx 0305-7453x 1460-2091 |
856 | 4 | u https://doi.org/10.1093/jac/dkad260y Fulltext |
856 | 4 | u https://uu.diva-portal.org/smash/get/diva2:1800390/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-512437 |
856 | 4 8 | u https://doi.org/10.1093/jac/dkad260 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.